Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

917.31 -20.13 (-2.15%)
Streaming Delayed Price Updated: 3:07 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
S&P 500: The Bull Market Is Just Getting Started
The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
Why Novo Nordisk Stock Is Sinking This Week
The global drugmaker is facing some headwinds related to tough competition. 
Via The Motley Fool
Topics Government World Trade
Why Nvidia (NVDA) Stock Is Falling Today
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment. 
Via Benzinga
Navigating the Shifting Tides: Experts Chart Course for 2025 Stock Market
As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Via Stocktwits
Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report
The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack. 
Via Stocktwits
Topics Government
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data
Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target. 
Via Stocktwits
Topics Government World Trade
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026. 
Via Benzinga
Topics Government
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Is the fourth time the charm for this Danish pharmaceutical giant? 
Via The Motley Fool
Topics Earnings
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs. 
Via Investor's Business Daily
Topics Government
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
My 6 Top-Ranked Stocks to Buy Right Now in November
Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list. 
Via The Motley Fool
Topics Artificial Intelligence
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration. 
Via Benzinga
Topics Government
Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone
The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut. 
Via Benzinga
Topics Economy Stocks
1 Mid-Cap Stock for Long-Term Investors and 2 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy. 
Via The Motley Fool
Microsoft Gets $135 Billion OpenAI Stake
Via The Motley Fool
The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market
In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025
As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus
As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced... 
Via MarketMinute
Topics Artificial Intelligence Economy
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
Market Recovers from Tariff Turmoil: Dow, S&P 500, and Nasdaq Stage Resilient Rebound Amid Shifting Economic Winds
The U.S. financial markets have demonstrated remarkable resilience in 2025, staging a significant rebound after experiencing a sharp selloff earlier in the year. The Dow Jones Industrial Average, S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.